On March 7, 2022 Genprex reported A new study publishedin Cancer Gene Therapy by independent researchers outlines REQORSA as a promising therapeutic candidate for combinational therapy in cancer (Press release, Genprex, MAR 7, 2022, View Source [SID1234609574])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Independent researchers at Meharry Medical College and Vanderbilt University recently published a study in Cancer Gene Therapy titled, "Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications."

The study provides an overview of TUSC2 (sometimes referred to as FUS1), which is the tumor suppressor gene used in Genprex’s REQORSA Immunogene Therapy. The study highlights TUSC2’s mechanism of action, the preclinical and clinical data of REQORSA in non-small cell lung cancer, and REQORSA’s ability to be combined with targeted therapies and immunotherapies; thus serving as an outside, unbiased affirmation to REQORSA and its potential as a therapeutic candidate in cancer.

Some of the study’s key highlights and supporting evidence of TUSC2 and Genprex’s clinical strategies include:

The deletion of TUSC2 in lung cancer – "FUS1/TUSC2 is a tumor suppressor gene that is frequently deleted in lung cancer." In fact, approximately 80% of all lung cancers lack or have low levels of the TUSC2 tumor suppressor protein.
TUSC2’s Mechanisms of Action – "FUS1/TUSC2 induces cancer cell death, increases apoptosis and inhibits cell proliferation."
Drug Resistance – "Conventional therapy for metastatic NSCLC currently uses epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors such as osimertinib. Beside toxicity, this type of therapy often leads to treatment-resistant cancer as a result of selecting tumor cell clones carrying mutations, thus leading to drug resistance." In addition to targeted therapies, "effectiveness of immunotherapeutics is limited due to evasion of tumor cells from immunosurveillance mechanisms eventually leading to tumor resistance similar to chemotherapy."
TUSC2 as a Combination Therapy – On targeted therapies: "Ability of FUS1/TUSC1 to suppress receptor and non-receptor kinases as well as sensitize NSCLC cells to chemotherapeutics makes this tumor suppressor a promising therapeutic candidate for combinational therapy." On immunotherapies: "REQORSA and anti-PD-1 combined therapy demonstrated significantly stronger immune response than individual therapies." On chemotherapy: "FUS1/TUSC2 is a promising adjuvant for successful anti-tumor chemotherapy."
TUSC2 May Benefit Many Types of Cancer – "The localization of tumor suppressor genes in the 3p21 region was reinforced by detection of deletions in this area in other solid (breast, cervix, and renal carcinoma) and hematopoietic (chronic myeloid leukemia) tumors."
TUSC2 May Benefit Other Diseases and Infections – "FUS1-dependent mechanisms are relevant in etiologies of diseases beyond cancer, such as chronic inflammation, bacterial and viral infections, premature aging, and geriatric diseases."
To read the article in its entirety, click here. For more information and additional studies supporting TUSC2, please refer to our Bibliography Page.

This research paper was not sponsored Genprex and the Company has no affiliation with the researchers or the research paper.